| Name | Title | Contact Details |
|---|---|---|
Thomas Trimarchi |
President and Chief Financial Officer | Profile |
Laura Woodhead |
SVP, Deputy General Counsel | Profile |
Adora Ndu |
Chief Regulatory Officer and EVP | Profile |
Matty Taga-Allen |
Vice President, People Operations, Compliance and Executive HRBP | Profile |
Christine Liu |
Vice President, Legal | Profile |
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs.
Shape Therapeutics (ShapeTx) is a development-stage biotechnology company establishing itself as the leader in next-generation gene therapy.
Guava Technologies, Inc. is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Imerjent is a Wilsonville, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.